Adagrasib in the Treatment of KRAS p.G12C Positive Advanced NSCLC: Design, Development and Place in Therapy
Drug Design, Development and Therapy · 2024-12 · Volume 18 · 5673-5683
DOI: 10.2147/dddt.s466217 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Drug Design, Development and Therapy, 2024-12. Verfasst von Brian Warnecke und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of California Irvine School of Medicine, Chao Family Comprehensive Cancer Center, Orange, CA, USA. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins p21(ras), Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, University of California Irvine School of Medicine, Chao Family Comprehensive Cancer Center, Orange, CA, USA.
- Department of Medicine, St. Marianna University School of Medicine, Kawasaki, Japan.
ORCID-Profile: Misako Nagasaka
Zitieren
APA
Warnecke, B., & Nagasaka, M. (2024). Adagrasib in the Treatment of KRAS p.G12C Positive Advanced NSCLC: Design, Development and Place in Therapy. Drug Design, Development and Therapy, Volume 18, 5673-5683. https://doi.org/10.2147/dddt.s466217
Vancouver
Warnecke B, Nagasaka M. Adagrasib in the Treatment of KRAS p.G12C Positive Advanced NSCLC: Design, Development and Place in Therapy. Drug Design, Development and Therapy. 2024;Volume 18:5673-5683. doi:10.2147/dddt.s466217
BibTeX
@article{Warnecke2024,
author = {Warnecke, Brian and Nagasaka, Misako},
title = {Adagrasib in the Treatment of KRAS p.G12C Positive Advanced NSCLC: Design, Development and Place in Therapy},
journal = {Drug Design, Development and Therapy},
year = {2024},
volume = {Volume 18},
pages = {5673--5683},
doi = {10.2147/dddt.s466217}
}
EUVIMED